When 7 isn't 7: glycohemoglobin and chronic kidney disease

Area of Science:

• Endocrinology
• Nephrology
• Clinical Chemistry

Background:

• Glycohemoglobin (A1c) is the gold standard for assessing glycemic control in diabetes management.
• Clinical decisions and healthcare reimbursement are increasingly reliant on A1c values.
• Certain conditions can disrupt the correlation between A1c and mean blood glucose levels.

Purpose of the Study:

• To review the process of hemoglobin glycation.
• To examine how chronic kidney disease (CKD) affects hemoglobin glycation.
• To explore alternative methods for assessing glycemic control in patients with CKD.

Main Methods:

• Literature review on hemoglobin glycation and its alterations in CKD.
• Analysis of studies comparing A1c with mean blood glucose in diabetic patients with CKD.
• Evaluation of alternative glycemic assessment methods.

Main Results:

• Hemoglobin glycation, measured by A1c, can be inaccurately low or high in patients with CKD.
• CKD affects red blood cell lifespan and kidney function, impacting A1c interpretation.
• Alternative methods like continuous glucose monitoring (CGM) may offer a more accurate glycemic assessment in CKD.

Conclusions:

• A1c may not accurately reflect glycemic control in patients with CKD.
• Healthcare providers should consider CKD when interpreting A1c results.
• Alternative glycemic monitoring strategies are crucial for optimal diabetes management in CKD patients.